Harnessing the Power of
Naturally Occurring NK Cells
to Fight Cancer
Indapta Therapeutics is a biotechnology company focused on developing
and commercializing a proprietary, off-the-shelf, allogeneic FcRγ-deficient
natural killer (G-NK) cell therapy to treat multiple types of cancer.
Harnessing the Power of Naturally Occurring NK Cells to Fight Cancer
Indapta Therapeutics is a biotechnology company focused on developing and commercializing a proprietary, off-the-shelf, allogeneic FcRγ-deficient natural killer (G-NK) cell therapy to treat multiple types of cancer.
ABOUT US
Indapta is a biotechnology company harnessing the natural power of the immune system to fight hematologic and solid cancers with its universal natural killer (NK) cell platform derived from healthy donors. The company’s allogeneic platform is based on a subset of NK cells that are deficient in the FceR1g protein, and are called g-NK cells (g minus NK cells). These cells are particularly potent at killing cancer cells when combined with monoclonal antibodies. Indapta is working to bring this off-the-shelf cellular therapy to cancer patients to address the limitations of currently available immunotherapies. Indapta is based in Houston, TX, and Seattle, WA.
G-NK cell therapy is an off-the-shelf solution, eliminating the need for a patient-specific therapy.
G-NK cell therapy is combined with FDA-approved tumor-targeting antibodies.
LEADERSHIP
Robert Sikorski, MD
Acting Chief Medical Officer
Mark W. Frohlich, M.D.
Chief Executive Officer
Guy DiPierro
Co-Founder
Austin Bigley, PH.D.
VP of Research
Stefanie Mandl-Cashman
Chief Scientific Officer
Linda Barnes
Head of Regulatory & Quality
Sungjin Kim, Ph.D.
Scientific Founder, Indapta; Associate Professor, Department of Medical Microbiology and Immunology, University of California, Davis
John Sunwoo, M.D.
Scientific Founder, Indapta; Professor, Stanford University School of Medicine
Todd A. Fehniger, M.D., Ph.D.
Associate Professor, Department Of Medicine, Oncology Division, Washington University School Of Medicine
Nina Shah, M.D.
Clinical Professor of Medicine, University of California, San Francisco
Vaughn Smider, M.D., Ph.D.
Associate Professor, Department of Molecular Medicine, Scripps Research Institute
Ronald Martell
Chairman of the Board and Co-Founder, Indapta
Fabio Pucci, Ph.D.
Senior Director of Venture Investments Health, Leaps by Bayer
Laura Stoppel, PH.D.
Principal, RA Capital Management, LP
Jim Weiss
Founder and Chairman, Real Chemistry
Lori Hu
Managing Director, Vertex Ventures HC
Ran Nussbaum
Co-Founder and Managing Partner at The Pontifax Group
Mark W. Frohlich, M.D.
Chief Executive Officer, Indapta
SCIENCE AND PLATFORM
Cancer is the leading cause of death worldwide. Current therapies are suboptimal, frequently ineffective and often cause significant side effects.
Immunotherapies are a formidable new mechanism to fight cancer. Designed to boost the immune response, immunotherapies such as G-NK therapy were developed to address the limitations of currently available autologous T-cell therapies.
Indapta is developing a universal, allogeneic NK cell therapy designed to substantially improve the cytotoxicity of antibody therapy in cancer. Engineered by nature to fight cancer and infectious diseases, Indapta’s NK cell platform is based on a naturally occurring subset of natural killer cells known as g-NK cells that that have undergone epigenetic changes including the down-modulation of the FceR1γ chain. Compared to conventional NK cells, g-NK cells demonstrate increased cytokine secretion, higher levels of cytolytic enzymes, a more favorable metabolic profile, increased persistence, and markedly higher antibody dependent cell mediated cytotoxicity (ADCC).
Indapta has demonstrate robust anti-cancer effects in preclinical models of cancer using g-NK cells in combination with rituximab in NHL, and in combination with daratumumab in multiple myeloma. These effects are markedly superior to conventional NK cells in combination with monoclonal antibodies.
Indapta has developed a proprietary process to expand g-NK cells that yields a highly potent product without the need for artificial genetic engineering. The company’s first-in-human Phase 1 trial will treat relapsed/refractory non-Hodgkin’s lymphoma and multiple myeloma patients with g-NK cells in combination with rituximab and daratumumab, respectively.
EXPANDED ACCESS POLICY
Indapta’s Expanded Access Policy (EAP) covers the use of its investigational products outside of an ongoing clinical trial. Indapta appreciates the need for additional treatments for patients who have serious or immediately life-threatening diseases and have limited available treatment options. The decision to establish an EAP is dependent on a number of key factors consistent with the US Food and Drug Administration (FDA) and other regulatory agencies’ requirements. These include, but are not limited, to the following:
• The illness for which the investigational cell therapy is being considered must be serious or life-threating, with no other satisfactory treatment options (such as approved products or enrolling clinical trials);
• There is sufficient evidence that the potential benefit of the investigational drug to the patient would outweigh the potential risks, based on all available safety and efficacy information; and
• Providing the investigational cellular immunotherapy as part of an EAP will not interfere with the enrollment of clinical trials to support the development and marketing approval. Based on these factors and the early stage of clinical development for our products, Indapta believes that participation in our clinical trials is the appropriate means to access our investigational cellular immunotherapies.
Therefore, Indapta does not currently have an expanded access program. If you are a patient seeking access to our investigational product(s), please contact your treating healthcare provider.
For more information about our ongoing clinical trials, please refer to www.clinicaltrials.gov, study number NCT06119685. Healthcare providers who are interested in learning more about clinical program(s) and investigational product(s) and/or participation in our clinical trial(s), please contact trials@indapta.com.
RECENT NEWS
Indapta Therapeutics Presents Clinical and Preclinical Data of Allogenic Natural Killer Cell Therapy at Society for Immunotherapy of Cancer Meeting
Indapta Therapeutics Announces FDA Clearance of IND for Phase 1 Trial of IDP-023 for Progressive Multiple Sclerosis
We are excited to share that profiled Indapta in a new editor’s pick feature. Our CSO shares how focusing on the power of naturally occurring NK cells, we're able to bring new hope to those faced with hard-to-treat conditions like cancer and autoimmune disorders.
Read the piece to learn more about our IND filings and expanding pipeline!
CEO Mark Frohlich interviewed for Pharmaverse Podcast
Indapta Therapeutics to Highlight its g-NK Cell Platform for the Treatment of Cancer and Autoimmune Disease in a Plenary Session at New York Academy of Sciences Frontiers in Cancer Immunotherapy Conference
Indapta Therapeutics Awarded $4.5 Million by CPRIT to Advance Clinical Development of its Allogenic Natural Killer Cell Therapy
Indapta Therapeutics receives U.S. FDA Fast Track Designation for Lead Clinical Drug Candidate IDP-023 for Non-Hodgkin's Lymphoma and Myeloma
Indapta CEO Mark Frohlich interviewed for Multiple Myeloma Research Foundation Accelerator Magazine 25th Anniversary Issue
Indapta Therapeutics Announces First Patients Treated with IDP-023 Allogeneic Natural Killer (NK) Cell Therapy for Cancer
Indapta CEO, Mark Frohlich, to participate in panel, “Beyond CAR-T, What’s Next for Cell Therapy?
Indapta IND cleared by FDA
Indapta Therapeutics Names Moya Daniels, Sneior Vice President of Regulatory and Clinical Operations
Indapta Therapeutics CEO, Mark Frohlich is interviewed by WuXi Apptec on "Delivering on the Promise of New Modalities"
Indapta Therapeutics CEO, Mark Frohlich, interviewed by the San Francisco Business Times
Indapta Therapeutics names Mark W. Frohlich, MD., Chief Executive Officer and raises over $50 million in series A financing and commitments to Advance Development of G-NK Cell Theraphy to Treat Multiple Types of Cancer
Indapta Therapeutics announces New Preclinical Data Demonstrating Proprietary G-NK Cells Enhance Efficacy of Monoclonal Antibodies in Multiple Myeloma
Indapta Therapeutics announces Ley Managment Team Appointments to Advance into Clinial Trials in 2021
Multiple Myeloma Research Foundation (MMRF) and Indapta Therapeutics announce Investments to Advance Clinical Development of Natral Killer Cell Therapy
Indapta Therapeutics Appoints Dov Goldstein, M.D., Chief Financial and Business Officer
Indapta Therapeutics Provides Corporate Update
Indapta Therapeutics and Lonza Announce Strategic Partnership to Advance a Next-generation, Off-the-shelf, Allogeneic Immuno-oncology Therapy
CORPORATE PRESENTATION
Indapta has demonstrated robust anti-cancer effects in preclinical models of cancer using g-NK cells in combination with rituximab in NHL, and in combination with daratumumab in multiple myeloma. These effects are markedly superior to conventional NK cells in combination with monoclonal antibodies.
PUBLICATIONS
Indapta has demonstrated robust anti-cancer effects in preclinical models of cancer using g-NK cells in combination with rituximab in NHL, and in combination with daratumumab in multiple myeloma. These effects are markedly superior to conventional NK cells in combination with monoclonal antibodies.
Careers
Become a part of our dynamic team at Indapta Therapeutics and embark on an exciting journey. Join us in making a meaningful impact on the lives of patients worldwide through innovative therapies and cutting-edge science